Chemotherapy for advanced ovarian cancer

Cochrane Database of Systematic Reviews

Volumn 2011, Issue 4, 1999, Pages

  Stewart, Lesley Anne ^a,b   Aabo, K ^b   Adams, M ^b   Adnitt, P ^b   Alberts, D S ^b   Athanazziou, A ^b   Barley, V ^b   Bell, D R ^b   Bianchi, U ^b   Blessing, J ^b   Bolis, G ^b   Brady, M F ^b   Brodovsky, H S ^b   Bruckner, H ^b   Buyse, M ^b   Canetta, R ^b   Chylak, V ^b   Cohen, C J ^b   Colombo, N ^b   Conte, P F ^b   Crowther, D ^b   De Oliveira, C F ^b   Edmonson, J H ^b   Gennatas, C ^b   Gilbey, E ^b   Gore, M ^b   Guthrie, D ^b   Kaye, S B ^b   Laing, A H ^b   Landoni, F ^b   Leonard, R C ^b   Lewis, C ^b   Liu, P Y ^b   Mangioni, C ^b   Marsoni, S ^b   Meerpohl, H ^b   Muller, U ^b   Omura, G A ^b   Parmar, M K B ^b   Pater, J ^b   Pecorelli, S ^b   Presti, M ^b   Sauerbrei, W ^b   Skarlos, D V ^b   Smalley, R V ^b   Solomon, H J ^b   Sturgeon, J F G ^b   Tattersall, M H N ^b   Wharton, J T ^b   ten Bokkel Huinink, W W ^b   Tomirotti, M ^b   Torri, W ^b   Trope, C ^b   Turbow, M M ^b   Vermorken, J B ^b   Webb, M J ^b   Wilbur, D W ^b   Williams, C J ^b   Wiltshaw, E ^b   Wood, R ^b   Yeap, B Y ^b   more..

^a UNIVERSITY OF YORK   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85102701483     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001418     Document Type: Review

References (70)

1. Aabo K, Hald I, Horbov S, Dombernowsky P, Hansen H, Sorensen H, et al. A randomised study of single agent vs combination chemotherapy in FIGO stages IIB, III and IV ovarian adenocarcinoma. European Journal of Cancer and Clinical Oncology 1985;21:475-81.
2. Brodovsky HS, Bauer M, Horton J, Elson PJ. Comparison of melphalan with cyclophosphamide, methotrexate and 5-fluorouracil in patients with ovarian cancer. Cancer 1984;53:844-52.
3. Bruckner H, Pagano M, Falkson G, Creech R, Arseneau J, Horton H, et al. Controlled prospective trial of combination chemotherapy with cyclophosphamide, Adriamycin and 5-fluorouracil for the treatment of advanced ovarian cancer: a preliminary report. Cancer Treatment Reports 1979;63:297-9.
4. Omura GA, Morrow CP, Blessing JA, Miller A, Buchsbaum H, Homesley H, et al. A randomised comparison of melphalan versus melphalan plus hexamethylmelamine versus Adriamycin plus cyclophosphamide in ovarian carcinoma. Cancer 1983;51:783-9.
5. Park RC, Blom J, Disaia PJ, Lagasse LD, Blessing JA. Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5-fluorouracil and dactinomycin or with the combination of Cytoxan, 5-fluorouracil and dactinomycin. Cancer 1980;45:2529-42.
6. Edmonson JH, Flemming TR, Decker DG, Malkasian G, Jorgensen E, Jefferies J, et al. Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal residual disease. Cancer Treatment Reports 1979;61:355-7.
7. Wharton JT, Edwards CL, Rutledge FN. Long-term survival after chemotherapy for advanced epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology 1984;148:997-1005.
8. Wharton JT, Edwards CL, Rutledge FN. Long-term survival after chemotherapy for advanced epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology 1984;148:997-1005.
9. Bolis G, Bortolozzi G, Carinelli G, et al. Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer. Cancer Chemotherapy and Pharmacology 1980;4:129-32.
10. Medical Research Council Working Party on Ovarian Cancer. Medical Research Council study on chemotherapy in advanced ovarian cancer. British Journal of Obstetrics and Gynaecology 1981;88:1174-85.
11. Miller A, Klaassen DJ, Boyes DA, Dodds D, Gerlath, Kirk M, et al. Combination v sequential therapy with melphalan, 5-fluorouracil and methotrexate for advanced ovarian cancer. Canadian Medical Association Journal 1980;123:363-71.
12. Turbow MM, Jones H, Yu VK, Greenberg B, Hannigan J, Torti FM. Chemotherapy of ovarian carcinoma: a comparison of melphalan vs Adriamycin-cyclophosphamide. Proceedings of the American Association of Cancer Research and American Society of Clinical Oncology. 1980; Vol. 21:196 Abstract 785.
13. Tropé C. Melphalan with and without doxorubicin in advanced ovarian cancer. Obstetrics and Gynecology 1987;70:582-6.
14. Chylak V, Kolaric K, Krusic K. Controlled clinical trial of chemotherapy in advanced ovarian cancer - cyclophosphamide mono-chemotherapy versus a combination of Adriamycin, cyclophosphamide, 5-fluorouracil and methotrexate. Lijec Vjesen 1986;109:230-4.
15. Sturgeon JFG, Fine S, Gospodarowicz MK, Dembo AJ, Bean HA, Bush RS, et al. A randomised trial of melphalan alone vs combination chemotherapy in advanced ovarian cancer. Proceedings of the American Society for Clinical Oncology. 1982; Vol. 1:abstract C-148.
16. Medical Research Council Gynaecological Cancer Working Party. Inadequacy of trials of chemotherapy in advanced ovarian carcinoma: a randomised trial of three regimens. a randomised trial of three regimens. (unpublished).
17. Bell Dr, Woods RK, Levi JA, Fox RM, Tattersall MHN. Advanced ovarian cancer: a prospective randomised trial of chlorambucil versus combined cyclophosphamide and cisdiamminedichloroplatinum. Australian and New Zealand Journal of Medicine 1982;12:245-9.
18. Wadler S, Yeap B, Vogl S, Carbone P. Randomised trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian cancer: initial and long-term results: Eastern Cooperative Oncology Study Group E2878. Cancer 1996;77:733-42.
19. Leonard RC, Smart GE, Livingstone JRB, Cornbleet MA, Kerr GR, Fletcher S, et al. Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma. Cancer Chemotherapy and Pharmacology 1989;23:105-110.
20. Crowther D. A randomised trial of chemotherapy in advanced residual (stage Iib-IV) ovarian cancer. Manchester Ovarian Cancer Clinical Study Group protocol, 1996.
21. Williams CJ, Mead GM, Macbeth FR, Thompson J, Whitehouse JMA, MacDonald H, et al. Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomised trial. Journal of Clinical Oncology 1985;3:1455-62.
22. Gynaecological Group, Clinial Oncological Society of Australia and the Sydney Branch, Ludwig Institute for Cancer Research. Chemotherapy of advanced ovarian adenocarcinoma: a randomised comparison of combination versus sequential therapy using chlorambucil and cisplatin. Gynecologic Oncology 1986;23:1-13.
23. Masding J, Sarkar T, White JF, Barley VL, Chawla SL, Boesen T, et al. Intravenous treosulfan versus intravenous treosulfan plus cisplatinum in advanced ovarian carcinoma. British Journal of Obstetrics and Gynaecology 1990;97:342-51.
24. Wilbur DW, Rentschler RE, Wagner RJ, Keeney ED, King A, Hilliard DA. Randomised trial of the addition of cisplatin (DDP) and/or BCG to cyclophosphamide (CTX) chemotherapy for ovarian carcinoma. Journal of Surgical Oncology 1987;34:165-9.
25. Decker DG, Thomas MD, Fleming R, Malkesian GD, Webb MD, Jefferies JA, et al. Cyclophosphamide plus cisplatinum in combination: treatment program for stage III or IV ovarian carcinoma. Obstetrics and Gynecology 1982;60:418-27.
26. De Oliveira CF, Lacave AJ, Villani C, Wolff JP, Di Re F, Namer M, et al. Randomised comparison of cyclophosphamide, doxorubicin and cisplatin for the treatment of advanced ovarian cancer. European Journal of Gynaecological Oncology 1990;11:323-30.
27. Omura G, Blessing JA, Ehrlich CE, Miller A, Yordan E, Creasman WT, et al. A randomised trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer 1986;57:1725-30.
28. Turbow MM. Chemotherapy of advanced ovarian cancer: Adriamycin-cyclophosphamide versus platinum-Adriamycin-cyclophosphamide. Norther California Oncology Group protocol 5091, 1980. Adriamycin-cyclophosphamide versus platinum-Adriamycin-cyclophosphamide. Norther California Oncology Group protocol 5091, 1980. (unpublished).
29. Trope C, Anderson H, Björkholm E, Frankendal B, Himmelman A, Högberg T, et al. Doxorubicin-melphalan with and without cisplatin in advanced ovarian cancer. Ten-year survival results from a prospective randomised study by the Swedish Cooperative Ovarian Cancer Study Group. Acta Oncologica 1996;35:109-18.
30. GICOG. Long-term results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide and adriamycin in advanced ovarian cancer. Gynecologic Oncology 1992;45:115-17.
31. Skarlos DV, Aravantinos G, Kosmidis P, Pavlidis N, Gennatas K, Beer M, et al. Carbo alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic Cooperative Oncology Study Group. European Journal of Cancer 1996;32:421-8.
32. Tomirotti M, Perrone S, Gie P, Canaletti R, Carpi A, Biasoli R, et al. Cisplatin (P) versus cyclophosphamide, adriamycin and cisplatin (CAP) for stage III-IV epithelial ovarian carcinoma: a prospective randomised trial. Tumori 1988;74:573-7.
33. Cohen CJ, Goldberg JD, Holland JF, Bruckner HW, Deppe G, Gusberg SB, et al. Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO stages III and IV) as measured by surgical end-staging (second-look) operation. American Journal of Obstetrics and Gynecology 1983;145:955-65.
34. Athanassiou A, Pectasides D, Varthalitis J, Barbounis V, Dimitriadis M, et al. Carboplatin (C) versus C + ifosfamide (I) + vincristine (V) + bleomycin (B) in epithelial ovarian cancer (OC). Annals of Oncology 1990;1:2-25 (suppl).
35. Wiltshaw E, Evans B, Rustin G, Gilbey E, Baker J, Barker G. A prospective randomised trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma. Journal of Clinical Oncology 1986;4:722-9.
36. Rankin EM, Mill L, Kaye SB, Atkinson R, Cassidy L, Cordiner J, et al (1992). A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer. British Journal of Cancer 61992;5:275-81.
37. Gilby E, Pollard W, Bamford D, Barley V, Jelen I, Hale BT, et al. Ovarian Cancer Trial, 1986. Southwest Oncology Study.
38. Gilby E, Pollard W, Bamford D, Barley V, Jelen I, Hale BT, et al. Ovarian Cancer Trial, 1986. Southwest Oncology Study.
39. Gennatas C, Alamanos J, Dardoufas C, Kovaris J, Androulakis G. Carboplatin, epirubicin and cyclophosphamide versus cisplatin, epirubicin and cyclophosphamide: a phase III randomised trial in stages III and IV epithelial ovarian cancer. Proceedings of the American Society for Clinical Oncology. 1992; Vol. 11:720.
40. Ten Bokkel Huinik WW, van der Burg ME, van Oosterom AT, Neijt JP, George M, Gustalla JP, et al. Carboplatin in combination chemotherapy for ovarian cancer. Cancer Treatment Reviews 1988;15:9-15 (suppl).
41. Mangioni C, Bolis G, Pecorelli S, Bragman K, Epis A, Favalli G, et al. Randomised trial in advanced ovarian cancer comparing cisplatin and carboplatin. Jounal of the National Cancer Institute 1989;81:1464-71.
42. Meerpohl HG, Kuhnle J, Sauerbrei W, Achterrach W, Pfeiderer A (1990). Cyclophosphamide/cisplatin (CTX/PT) cs CTX/carboplatin (CarboPT) in advanced ovarian carcinoma: a randomised multicentre study. 1120.
43. Conte PF, Bruzzone M, Carnin F, Chiara S, Donadio M, Facchini V, et al. Carboplatin, doxorubicin and cyclophosphamide versus cisplatin, doxorubicin and cyclophosphamide: a randomised trial in stage III-IV epithelial ovarian carcinoma. Journal of Clinical Oncology 1991;9:658-63.
44. Kato T, Nishimura H, Yamabe T, Terashima Y, Kasamatsu T, Hirabayashi K, et al. Phase III study of carboplatin for ovarian cancer. Japanese Journal of Cancer Chemotherapy 1988;15:2297-304.
45. Edmonson JH, McCormack Gm, Wieand HS, Kugler HW, Krook JE, Stanhope CR, et al (1989). Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens. Journal of the National Cancer Institute 1989;81:1500-4.
46. Anderson H, Wagstaff J, Crowther D, Evans A, Johansen K, Franks CR. Comparitive toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer. European Journal Cancer and Clinical Oncology 1988;24:1471-9.
47. Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J, et al. Cisplatin - cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomised phase III study of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 1992;10:718-26.
48. Taylor AE, Wiltshaw E, Gore M, Fryatt I, Fisher C. Long-term follow up of the first randomised study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. Journal of Clinical Oncology 1994;12:2066-70.
49. Alberts DS, Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomised trial in stages III and IV ovarian cancer. Journal of Clinical Oncology 1992;10:706-17.
50. Adams M, Kerby IJ, Rocker I, Evans A, Johansen K, Franks CR (1989). A comparison of toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. Acta Oncologia 1989;28:57-60.
51. Adams M, Johansen KA, James KW, Rocker I. A controlled clinical trial in advanced ovarian cancer. Clinical Radiology 1982;33:161-3.
52. Barlow JJ, Lele SB, Emrich LJ. Long-term survival rates with various chemotherapeutic regimens in stage III and IV ovarian adenocarcinoma. American Journal of Obstetrics and Gynecology 1985;152:310-4.
53. Belpomme D, Bugat R, Rives M, Pinon G, Roullet B, Facchini T, et al. Carboplatin versus cisplatin as first line therapy in stage III-IV ovarian carcinoma: results of an ARTAC phase III trial. 722.
54. Carmo-Pereira J, Oliveira Costa F, Henriques E, Almeida Ricardo J. Advanced ovarian carcinoma: a prospective and randomised clinical trial of cyclophosphamide vs combination cytotoxic chem (Hexa-CAF). Cancer 1981;48:1947-51.
55. Carmo-Pereira J, Oliveira Costa F, Henriques E. Cis-platinum, Adriamycin and hexamethylmelamine vs cyclophosphamide in advanced ovarian carcinoma. Cancer Chemotherapy and Pharmacology 1983;10:100-3.
56. De Palo G, De Lena M, Bonadonna G. Adriamycin vs Adriamycin plus melphalan in advanced ovarian carcinoma. Cancer Treatment Reports 1977;61:355-7.
57. Delgado G, Smith FP, McLaughlin Ek, Tuholski N. Single agent vs combination chemotherapy for ovarian cancer. American Journal of Clinical Oncology 1985;8:33-7.
58. Gronroos M, Nieminen U, Kauppila A, Kauppila O, Saksela E, Vayrynen M. A prospective randomised national trial for treatment of ovarian cancer: the role of chemotherapy and external radiation. European Journal of Obstetrics Gynecology and Reproductive Biology 1984;17:33-42.
59. Harvey HA, Lipton A, Simmonds M, White D, Gottloeb R, Bernath A, et al. A randomised trial of Alkeran versus cyclophosphamide, hexamethylmelamine. Adriamycin and cisplatin combination chemotherapy in advanced ovarian carcinoma. Clinical research 1982;30:418.
60. Senn HJ, Lei D, Castano-Almendral A, Brunner K, Martz G, Obrecht P, et al. Chemo-mormono therapy for FIGO stage III and IV ovarian cancer. prospective SAKK study 20/77 [Chemo-(hormon)-therapie fortgeschrittener ovarialkarzinome der FIGO-stadien III and IV. Prospective SAKK-studie 20/71]. Schweizerische medizinische Wochenschrift 1980;110:1202-8.
61. Young RC, Chabner BA, Hubbard SP, Fisher R, Bender R, Anderson T, et al. Advanced ovarian carcinoma: a prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. The New England journal of medicine 1978;299:1261-6.
62. Bajorin D, Sarosdy MF, Poster DG, et al. Randomised trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumours. A Multi-institutional study. Journal of Clinical Oncology 1993;11:598-606.
63. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Statistics in Medicine 1982;1:121-129.
64. Horwich A, Sleijfer D, Fossa S, et al. A trial of carboplatin-based chemotherapy in good prognosis metastatic testicular non seminoma. Proceedings of the American Society of Clinical Oncology 1994;13:231 (abstract 709).
65. Ovarian Cancer Meta-analysis Project. CP versus CAP chemotherapy of ovarian carcinoma: a meta-analysis. Journal of Clinical Oncology 1991;9:1669-1679.
66. Parkin DM, Laara E, Muir CS. Estimates of the worldwide frequency of sixteen major cancers in 1980. International Journal of Cancer 1988;41:184-97.
67. Torri V on behalf of the International Ovarian Neoplasm Studies. Randomised study of cyclophosphamide, doxorubicin and cisplatin (CAP) vs single-agent carboplatin in ovarian cancer patients requiring chemotherapy: interim results of ICON2. Proceedings of the American Society of Clinical Oncology. 1996; Vol. 15:752.
68. Yusuf S, Peto R, Lewis J, Collins R, Sleight T. Beta blockade during and after myocardial infarction: an overview of randomised clinical trials. Progress in Cardiovascular Disease 1985;27:335-71.
69. Advanced Ovarian cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. BMJ 1991;303:884-93.
70. Advanced Ovarian Cancer Trialists' Group. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomised trials. British Journal of Cancer 1998;78:1479-87.